Overview

P2X7 Receptor Antagonists Market Overview:

P2X7 receptor, an ATP-gated and non-selective cation channel that can regulate inflammatory disease has been implicated. The release of pro-inflammatory cytokines can be caused by the activation of the P2X7 channel by high levels of adenosine triphosphate (ATP). This has been linked to a wide range of diseases. There is currently no P2X7 antagonist on the market. Clinical trials have not yet begun to identify any P2X7 antagonists. P2X7R, a subtype of the seven purinergic P2X7 receptors that are ATP-gated, non-selective Cation Channels, is unique. There have been reports that P2X7R plays a pathological role in a variety of diseases, including arthritis, inflammatory bowel disease, neurodegenerative disorders, chronic pain, mood disorders, and cancers. Many pharmaceutical companies have attempted to develop a clinical candidate for P2X7R.
P2X7 receptor, an ATP-gated and non-selective cation channel, is associated with a variety of inflammatory disorders. P2X7 receptor antagonists are therapeutic agents. Pain management is a common use of opioid medications. P2X7R, a subtype of the seven purinergic P2X receptors (ATP-gated nonselective Cation Channels), is unique. The pathological role of P2X7R in various diseases has been documented, including neurodegenerative diseases and chronic pain, mood disorders, cancers, and arthritis. A P2X7 Receptor Antagonist, or RA, is a pain medication that blocks the brain's activity of the ligand. The P2X7 Receptor is an important molecule that initiates inflammatory processes within the body.

The approval and launch of an alternative pain management option are expected to be a breakthrough in this space. P2X7 has been linked to major depression. Animal studies have also shown that P2X7 antagonists can cause P2X7 to act in a way similar to antidepressants. Inflammation, mood disorders, and depression are all possible areas where P2X7 may be involved. Its antagonism could also help to modify treatment. Numerous research studies have shown that P2X7 channels are activated by the pro-inflammatory cytokines IL-1b, and IL-18. Extracellular ATP has a low affinity for P2X7, compared to other purinergic ion channel channels (P2X4, P2X3, etc.). The therapeutic benefits of P2X7 receptor antagonists are significant, since P2X7 receptors are associated with inflammation regulation, and all immune cells (lymphocytes macrophages monocytes, and lymphocytes) express P2X7.

FutureWise Market Research has instantiated a report that provides an intricate analysis of P2X7 Receptor Antagonists Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the P2X7 Receptor Antagonists Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the P2X7 Receptor Antagonists Market:
• GlaxoSmithKline Plc
• Johnson and Johnson
• AstraZeneca Plc
• RaQualia Pharma
• Evotec AG
• Asahi Kasei Corporation
• Pfizer
(Note: The list of the major players will be updated with the latest market scenario and trends)

P2X7 Receptor Antagonists Market Segmentation:
By Drug Product
• AKP-23494954/RQ-00466479
• EVT 401
• GSK1482160
• JNJ-55308942
• JNJ-54175446
• Others

By Application
• Central Nervous System Disorders
• Immunological Disorders
• Others

By End-User
• Hospital
• Ambulatory Surgical Center
• Pharmaceutical and Botechnology Companies

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the P2X7 Receptor Antagonists Market By Drug Product, By Application, By End-User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1. Objectives of the Study
  1.2. Market Definition
  1.3. Market Scope
       1.3.1. Years Considered for the Study
       1.3.2. Market Covered
  1.4. Currency
  1.5. Limitations
  1.6. Stakeholders

2. Research Methodology
  2.1. Research Data
       2.1.1. Secondary Data
              2.1.1.1. Key Data from Secondary Sources
       2.1.2. Primary Data
              2.1.2.1. Key Data from Primary Sources
  2.2. Market Size Estimation
  2.3. Market Breakdown and Data Triangulation
  2.4. Assumptions for the Study  

3. Executive Summary
  3.1. Market Outlook
  3.2. Segment Outlook
  3.3. Competitive Insights

4. P2X7 Receptor Antagonists Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of P2X7 Receptor Antagonists Market Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. P2X7 Receptor Antagonists Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. P2X7 Receptor Antagonists Market, By Drug Product Historical Analysis and Forecast 2022-2028 (USD Million)
  7.1. AKP-23494954/RQ-00466479
  7.2. EVT 401
  7.3. GSK1482160
  7.4. JNJ-55308942
  7.5. JNJ-54175446
  7.6. Others

8. P2X7 Receptor Antagonists Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million)  
  8.1. Central Nervous System Disorders
  8.2. Immunological Disorders
  8.3. Others

9. P2X7 Receptor Antagonists Market, By End-User Historical Analysis and Forecast 2022-2028 (USD Million)  
  9.1. Hospital
  9.2. Ambulatory Surgical Center
  9.3. Pharmaceutical and Botechnology Companies

10. North America P2X7 Receptor Antagonists Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   10.1. Introduction
   10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         10.2.1. U.S.A
         10.2.2. Canada
         10.2.3. Mexico
   10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America P2X7 Receptor Antagonists Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   11.1. Introduction
   11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         11.2.1. Brazil
         11.2.2. Venezuela
         11.2.3. Argentina
         11.2.4. Rest of Latin America
   11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe P2X7 Receptor Antagonists Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         12.2.1. Germany
         12.2.2. U.K        
         12.2.3. France
         12.2.4. Italy
         12.2.5. Spain
         12.2.6. Russia
         12.2.7. Poland
         12.2.8. Rest of Europe
   12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific P2X7 Receptor Antagonists Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   13.1. Introduction
   13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         13.2.1. Japan
         13.2.2. China
         13.2.3. India
         13.2.4. Australia and New Zealand
         13.2.5. ASEAN
         13.2.6. Rest of Asia Pacific
   13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   14.1. Introduction
   14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         14.2.1. GCC
         14.2.2. Israel
         14.2.3. South Africa
         14.2.4. Rest of MEA
   14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape  
   15.1. Global Landscape - Key Players, Revenue and Presence
   15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   15.3. Global Emerging Companies
   15.4. North America - Market Share Analysis and Key Regional Players
   15.5. Europe - Market Share Analysis and Key Regional Players
   15.6. Asia Pacific - Market Share Analysis and Key Regional Players
   15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   16.1. GlaxoSmithKline Plc
         16.1.1. Company Overview
         16.1.2. Product Portfolio
         16.1.3. SWOT Analysis
         16.1.4. Financial Overview
         16.1.5. Strategic Overview
   16.2. Johnson and Johnson
         16.2.1. Company Overview
         16.2.2. Product Portfolio
         16.2.3. SWOT Analysis
         16.2.4. Financial Overview
         16.2.5. Strategic Overview
   16.3. AstraZeneca Plc
         16.3.1. Company Overview
         16.3.2. Product Portfolio
         16.3.3. SWOT Analysis
         16.3.4. Financial Overview
         16.3.5. Strategic Overview
   16.4. RaQualia Pharma
         16.4.1. Company Overview
         16.4.2. Product Portfolio
         16.4.3. SWOT Analysis
         16.4.4. Financial Overview
         16.4.5. Strategic Overview
   16.5. Evotec AG
         16.5.1. Company Overview
         16.5.2. Product Portfolio
         16.5.3. SWOT Analysis
         16.5.4. Financial Overview
         16.5.5. Strategic Overview          
   16.6. Asahi Kasei Corporation
         16.6.1. Company Overview
         16.6.2. Product Portfolio
         16.6.3. SWOT Analysis
         16.6.4. Financial Overview
         16.6.5. Strategic Overview    
   16.7. Pfizer
         16.7.1. Company Overview
         16.7.2. Product Portfolio
         16.7.3. SWOT Analysis
         16.7.4. Financial Overview
         16.7.5. Strategic Overview

17. Pre and Post COVID-19 Impact
   17.1. Positive influence on the healthcare industry
   17.2. The financial disruption of the manufacturing sector
   17.3. Impact of COVID-19 on emerging companies
   17.4. Significant mandates in the regulations initiated by healthcare administrations
   17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures